Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence|
Approximately 1 tablespoon of blood will be collected from each subject.
|Study Start Date:||October 2012|
|Study Completion Date:||February 2013|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.
The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in blood. The aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in blood via simple fluorescence measurements. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/invasion
Please refer to this study by its ClinicalTrials.gov identifier: NCT01707758
|Principal Investigator:||Stephen Williamson, MD||University of Kansas Medical Center Cancer Center|